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Abstract
Background: CD38 is expressed in human airway smooth muscle (HASM) cells, regulates intracellular
calcium, and its expression is augmented by tumor necrosis factor alpha (TNF-α). CD38 has a role in
airway hyperresponsiveness, a hallmark of asthma, since deficient mice develop attenuated airway
hyperresponsiveness compared to wild-type mice following intranasal challenges with cytokines such as
IL-13 and TNF-α. Regulation of CD38 expression in HASM cells involves the transcription factor NF-κB,
and glucocorticoids inhibit this expression through NF-κB-dependent and -independent mechanisms. In
this study, we determined whether the transcriptional regulation of CD38 expression in HASM cells
involves response elements within the promoter region of this gene.
Methods: We cloned a putative 3 kb promoter fragment of the human cd38 gene into pGL3 basic vector
in front of a luciferase reporter gene. Sequence analysis of the putative cd38 promoter region revealed
one NF-κB and several AP-1 and glucocorticoid response element (GRE) motifs. HASM cells were
transfected with the 3 kb promoter, a 1.8 kb truncated promoter that lacks the NF-κB and some of the
AP-1 sites, or the promoter with mutations of the NF-κB and/or AP-1 sites. Using the electrophoretic
mobility shift assays, we determined the binding of nuclear proteins to oligonucleotides encoding the
putative cd38 NF-κB, AP-1, and GRE sites, and the specificity of this binding was confirmed by gel
supershift analysis with appropriate antibodies.
Results: TNF-α induced a two-fold activation of the 3 kb promoter following its transfection into HASM
cells. In cells transfected with the 1.8 kb promoter or promoter constructs lacking NF-κB and/or AP-1
sites or in the presence of dexamethasone, there was no induction in the presence of TNF-α. The binding
of nuclear proteins to oligonucleotides encoding the putative cd38 NF-κB site and some of the six AP-1
sites was increased by TNF-α, and to some of the putative cd38 GREs by dexamethasone.
Conclusion: The EMSA results and the cd38 promoter-reporter assays confirm the functional role of NF-
κB, AP-1 and GREs in the cd38 promoter in the transcriptional regulation of CD38.
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Background
CD38 is a pleiotropic protein that has enzymatic and
receptor functions [1-3]. It is a ~45-kDa glycosylated
transmembrane protein, with an extracellular domain
that has an enzyme activity which generates cyclic ADP-
ribose (cADPR) and ADPR from nicotinamide adenine
dinucleotide (NAD) [1]. CD38 is expressed in different
cells including airway smooth muscle (ASM) cells, where
its expression is confined to the plasma membrane [4]. In
ASM cells, CD38/cADPR signaling has a role in the regu-
lation of intracellular calcium ([Ca2+]i) [5-7]. Previous
studies from our laboratory showed that CD38 expression
and its enzymatic activities are augmented by TNF-α and
IL-13, cytokines that are implicated in the pathogenesis of
inflammatory airway diseases such as asthma [5,8]. The
regulation of CD38 expression by TNF-α requires NF-κB
activation and involves MAPK signaling in ASM cells
[9,10].
Glucocorticoids are used in the treatment of asthma [11]
which regulate gene expression via the glucocorticoid
receptor (GR)[12]. Upon activation by ligand binding, the
GR translocates to the nucleus and acts either as a tran-
scription factor or as an inhibitor of transcription factors
such as NF-κB or AP-1. We have previously shown that
TNF-α-induced CD38 expression in ASM cells is inhibited
by glucocorticoids through a mechanism that involves
decreased NF-κB activation [9].
Regulation of the CD38 gene has also been investigated in
human myeloid cells [13]. In these cells, CD38 expression
is induced by retinoic acid through the retinoic acid
response element located within the first intron of the
cd38 gene. Response elements for other transcription fac-
tors, including AP-1 have been described in other cell sys-
tems, including osteoblasts and osteoclasts [14] and in
these cell lines, TNF-α-induced activation of a cd38 pro-
moter fragment requires an intact AP-1 site. Sequence
analysis of a 3 kb putative cd38 promoter fragment (Gen-
Bank Accession # DQ091293) cloned from a human
erythropoietic cell line (K562 cells) in our laboratory
revealed binding sites for NF-κB, AP-1, and GR (summa-
rized in Table 1). To determine whether CD38 expression
in human ASM cells is regulated by TNF-α and glucocorti-
coid response elements (GREs), we measured the binding
of transcription factors and the GR to their respective
putative sites within this promoter region. Our results
demonstrate that TNF-α causes increased binding to the
NF-κB site and to some of the AP-1 sites, and that muta-
tions in either of the binding sites abolish promoter acti-
vation. Dexamethasone increases the binding of GR to
some of the GRE sites within the promoter and abolishes
promoter activation induced by TNF-α. These results dem-
onstrate that TNF-α regulates CD38 expression transcrip-
tionally through NF-κB and AP-1, and glucocorticoids
decrease this expression possibly by binding to GREs
within the promoter and/or also by decreased NF-κB- and
AP-1-mediated transcription.
Methods
Materials
Tris base, glucose, HEPES and TNF-α were purchased from
Sigma Chemical (St. Louis, MO). Hanks' balanced salt
solution (HBSS) and Dulbecco's modified Eagle's
medium (DMEM), Trizol, Lipofectamine™ 2000, Super-
script III reverse transcriptase and the 1 kb DNA ladder
were obtained from Invitrogen (Carlsbad, CA). Dual-Luci-
ferase Reporter assay system, pGL3 basic vector, pRL-TK
plasmid, GoTaqR Green Master Mix and EMSA kit were
purchased from Promega (Madison, WI). QuickChange
Site-Directed Mutagenesis kit was obtained from Strata-
gene (La Jolla, CA). The nuclear extraction kit was pur-
chased from Active Motif (Carlsbad, CA). Recombinant
human glucocorticoid receptor protein (RP-500) was
obtained from Affinity Bioreagents (Golden, CO). Anti-
bodies for p65 or p50 subunit of NF-κB, c-jun and c-fos
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA).
Promoter-luciferase reporter constructs and site directed 
mutagenesis
Genomic DNA was isolated from the human erythro-
leukemia cell line K562 and approximately 3 kb of the
cd38 promoter was amplified by PCR using the following
primers: 3181F 5'-TGATGCCTCCTGTTGGGGGTCTA-3'
and 3181R 5'-CGGGAAAGCGCTTGGTGGTG-3' (Gen-
Bank Acc. No. DQ091293). The reverse primer (3181R)
was phosphorylated using T4 polynucleotide kinase and
PCR was performed under the following conditions: 94°C
for 3 min denaturing, then 30 cycles of 94°C for 50 s,
59.6°C for 50 s, 72°C for 90 s, and a final extension at
72°C for 10 min to yield a 3240 bp fragment. A truncated
1.8 kb promoter was also amplified employing the same
Table 1: Putative binding sites for AP-1, NF-B and GRE in the 
cd38 promoter.
NF-B binding site Location Designator References
GGGATTCCTC -1728 to -1719 NF-CD38 (46)
AP-1 sites Location Designator References
TGAATCA -2915 to -2909 AP-1–6 (47,48)
TTGGTCA -2835 to -2829 AP-1–5 (49,50)
TTGACTCAT -2798 to -2789 AP-1–4 (51)
AACTACA -1041 to -1035 AP-1–3 (52)
TGCCTCA -993 to -987 AP-1–2 (49)
TGAGGCA -151 to -145 AP-1–1 (49)
GRE sites Location Designator References
TGTTCT -2662 to -2658 GRE-4 (53)
TGTTCT -1398 to -1393 GRE-3 (53)
TGTTCT -1069 to -1063 GRE-2 (53)
TGTTCT -881 to -875 GRE-1 (53)Respiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
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PCR program with annealing at 60°C using the primer
pairs 1378F 5'-GCATGCATATGTTCATTGTAGCACTAT-3'
and 3181R 5'-CGGGAAAGCGCTTGGTGGTG-3' which
was phosphorylated using T4 polynucleotide kinase. The
resulting 3 kb and 1.8 kb PCR fragments were gel purified,
cloned into pCR 3.1 Uni vector (Invitrogen) and the
reverse orientation was confirmed by sequencing at the
Advanced Genetic Analysis Center, University of Minne-
sota. The 3 kb and 1.8 kb (truncated) positive clones were
digested with HindIII/EcoRV and ligated into SmaI/Hin-
dIII digested pGL3 basic vector (Promega, WI, USA). This
enabled cloning of the larger and truncated promoter frag-
ments in the forward orientation to drive the expression
of the luciferase reporter gene. The 3 kb and the truncated
cd38 promoter fragments in the pGL3 basic vector were
confirmed by nucleotide sequence analysis. To mutate the
putative NF-κB and AP-1 binding sites, primers for
mutated NF-κB and AP-1 binding sites were designed
(Table 2). Putative binding sites are underlined and
mutated sequences are shown in bold font. Mutations of
the putative NF-κB or AP-1 binding sites in the promoter
constructs were performed by the QuickChange Site-
Directed Mutagenesis Method (Strategene, La Jolla, CA)
using Pfu Turbo polymerase. Template DNAs were
digested with the methylation-dependent restriction
enzyme DpnI. Bacteria were then transformed with DpnI-
digested DNA, and the cloned mutated constructs were
confirmed by sequencing.
Sequence analysis of the cd38 promoter
The GeneQuest module of Lasergene 6.0 program from
DNASTAR was used to identify the potential transcription
factor binding sites in the cd38  promoter. The 3 kb
sequence of the cd38  promoter was analyzed using
GeneQuest for the potential transcription factor binding
sites using tfd.dat file. Analysis revealed six AP-1 binding
sites, one NF-κB binding site and four GRE binding sites
within the cd38 promoter. The putative transcription fac-
tor binding sites on the cd38 promoter are shown in Table
1.
Human Airway Smooth Muscle Cell culture
Human airway smooth muscle (HASM) isolated from the
trachealis muscle and propagated as described previously
[9,10]. were used in this study. The cells were plated at a
density of 1.0 × 104 cells/cm2 and were cultured in DMEM
supplemented with 10% FBS, 2 mM L-glutamine, 100 U/
ml of penicillin, 0.1 mg/ml of streptomycin, and 0.25 µg/
ml of amphotericin B. HASM cells were transfected as
described below, then 24 hrs following transfection they
were growth-arrested by maintaining them for at least 24
hrs in arresting medium containing no serum, but in the
presence of transferrin and insulin prior to TNF-α (50 ng/
ml) or dexamethasone (1 µM) treatment and measure-
ment of luciferase reporter activity.
DNA Transfections
Transient transfections were performed with Lipo-
fectamine™ 2000 according to the manufacturer's instruc-
tions. Cells (0.5–1 × 105) in 500 µl of growth medium
without antibiotics were plated one day before transfec-
tion. For the transfection, 0.8 µg of the vector DNA and 2
µl of Lipofectamine™ 2000 in 50 µl of Opti-MEM® were
mixed gently and incubated for 5 min at room tempera-
ture. Diluted DNA and lipofectamine were mixed and
incubated for 20 min at room temperature to form com-
plexes which were added to each well, and incubated at
37°C for 6 hrs. The cells were growth-arrested 24 hrs fol-
lowing transfection before exposing to TNF-α and dexam-
ethasone. The cells were collected for luciferase reporter
activity (described below).
Luciferase reporter gene transactivation assay
Reporter gene assays were performed 24 hrs after transfec-
tion. Cell lysates were subjected to the Dual-Luciferase
Reporter assay system and luciferase activities were meas-
ured with a luminometer (Lumat LB9507; Berthold).
Cells were washed twice with phosphate-buffered saline
(PBS) with no calcium and magnesium, and covered (0.1
ml/well) with Passive Lysis Buffer (Promega). The cells
were then scraped, the lysate transferred to microcentri-
fuge tubes, which was mixed by vortexing for 15 s, then
passed a few times through a needle and used for the
reporter assay. A 20 µl aliquot of the lysate was mixed with
100 µl of luciferase assay reagent and placed in a lumi-
nometer to measure the firefly luciferase activity. The flu-
orescence was quenched by the addition of the Stop and
Glo buffer and Renilla luciferase activity was measured
after a 2 second delay. Firefly luciferase activities were nor-
malized to Renilla luciferase activity to account for trans-
fection efficiency. Samples were analyzed in triplicate and
the experiment was repeated at least twice.
Table 2: Sequences of the primers for the cd38 putative NF-κB and AP1–4 binding sites.
NFκB-mut-F 5'-GTGGAAGACAGTATGGCGATTCCTCAAAGATCTAGAACC-3' 39 bp
NFκB-mut-R 5'-GGTTCTAGATCTTTGAGGAATCGCCATACTGTCTTCCAC-3' 39 bp
AP1–4-mut-F 5'-CTTGGCATCATCTTTGACTTGTCTCTTTCTTGCAAATGC-3' 39 bp
AP1–4-mut-R 5'-GCATTTGCAAGAAAGAGACAAGTCAAAGATGATGCCAAG-3' 39 bp
The putative NF-κB and AP1–4 binding sites are underlined and the mutated sequences are shown in bold font.Respiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
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Nuclear protein extraction
Nuclear extracts were prepared from growth-arrested
HASM cells at confluence. The media were aspirated and
washed with ice-cold PBS containing phosphatase inhibi-
tors and the cells were scraped in 3 ml of the same buffer.
The cells were pelletted by centrifugation at 1000 × g for 5
minutes and the supernatant discarded. The cells were
resuspended in 500 µl 1× hypotonic buffer by pipetting
several times, transferred to a chilled microcentrifuge tube
and incubated for 15 mins on ice. Detergent (25 µl) was
added, vortexed for 10 sec and pelleted by centrifugation
at 14,000 × g  for 30 sec at 4°C. The supernatant was
removed and the nuclear pellet was resuspended in 50 µl
of complete lysis buffer and vortexed for 10 sec. The mix-
ture was incubated on ice for 30 min, vortexed briefly and
pelleted at 14,000 × g for 10 min at 4°C. The supernatant
(nuclear fraction) was aliquoted, protein content meas-
ured and stored at -80°C until use.
Electrophoretic mobility shift assay (EMSA)
The protein concentration of the nuclear extract was quan-
titated using the Bradford protein assay (Bio-Rad, Her-
cules, CA). EMSA was performed as described earlier
[9,10]. The double-stranded oligonucleotides containing
the consensus binding sites for NF-κB, AP-1, GRE and the
putative cd38 binding sites (as shown in Table 3) were
labeled with [γ-32P]ATP (3,000 Ci/mmol at 10 mCi/ml)
by T4 Polynucleotide Kinase (Promega, Madison, WI).
Nuclear extracts (5 µg) from HASM cells or 1 µg of recom-
binant human GR protein were incubated for 30 min at
room temperature with 0.4 pmol of double-stranded32P-
labeled oligonucleotide containing the consensus binding
sites in a total volume of 10 µl in a buffer containing 20%
glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 250
mM NaCl, 50 mM Tris-HCl (pH 7.5), and 0.25 mg/ml
poly (dI-dC). After 30 min at room temperature, samples
were separated on a nonreducing 4% polyacyrlamide gel
using 0.5 M TBE buffer. The gels were dried and autoradi-
ography carried out with intensifying screens at -70°C. To
confirm specificity of the EMSA, competition assays were
performed with a 100-fold excess of unlabeled NF-κB or
AP-1 probe, or the SP-1 probe as a nonspecific competitor.
Gel super shift assays were performed to confirm the spe-
cificity of the EMSA using anti-p65 or -p50 subunit of NF-
κB, and anti-c-jun and anti-c-fos antibodies.
Statistical analysis
HASM cells isolated from three different donors were used
in the experiments. The experiments involving EMSA and
transient transfections of the constructs were repeated
three times. The samples were compared by one-way
ANOVA with Bonferroni's test for multiple comparisons.
GraphPad PRISM statistical software program was used
for statistical analyses and significance established at P
value of ≤ 0.05.
Results
NF-κB, AP-1 and Glucocorticoid Receptor binding to the 
cd38 promoter
To investigate the transcriptional regulation of CD38
expression in HASM cells, we cloned a putative 3 kb pro-
moter fragment (GenBank Acc. No. DQ091293) from
K562 cells into the pGL3 basic vector. The cd38 promoter
sequence was examined for the presence of typical con-
sensus elements using the GeneQuest module of Laser-
gene 6.0 program from DNASTAR. We identified six AP-1,
one NF-κB, and four GRE motifs which are shown in
Table 1. Using the electrophoretic mobility shift assay
(EMSA), we examined whether transcription factors from
HASM nuclear extracts or recombinant human GR pro-
teins can bind to these putative binding sites following
exposure of cells to TNF-α and dexamethasone. Oligonu-
cleotides were synthesized from putative NF-κB, AP-1 and
GRE binding sites (Table 3). The specificity of the EMSA
was confirmed by competition experiments using unla-
beled oligonucleotide sequences and gel supershift assays
Table 3: Sequences of the Oligonucleotides used in the EMSAs.
NF-κB consensus 5'-AGTTGAGGGGACTTTCCCAGGC-3' 22 bp
NF-CD38 5'-AGTATGGGGATTCCTCAAAGAT-3' 22 bp
AP-1 consensus 5'-CGCTTGATGACTCAGCCGGAA-3' 21 bp
AP1–1 5'-GGAACTCTGAGGCAAGGGGTT-3' 21 bp
AP1–2 5'-GCTTTTCTGCCTCAGAGTCTT-3' 21 bp
AP1–3 5'-CTAGCCTAACTACAATTGGCC-3' 21 bp
AP1–4 5'-ATCATCTTTGACTCATCTCTTTC-3' 21 bp
AP1–5 5'-CCTTCCTTTGGTCAGTTACAC-3' 21 bp
AP1–6 5'-CAATTCTTGAATCATGCCTCT-3' 21 bp
GRE consensus 5'-TAGAGGATCTGTACAGGATGTTCTAGAT-3' 28 bp
GRE1 5'-AATGTCACAGATGTTCTCTTAATAAAGA-3' 28 bp
GRE2 5'-TTCCGAACTTCTGTTCTGTTTCCCTCAA-3' 28 bp
GRE3 5'-AAGCACTGCCATGTTCTCACTTATAAGT-3' 28 bp
GRE4 5'-GCCATTGTAACTGTTCTCCATCCTTATC-3' 28 bp
* The putative binding sites for the different transcription factors in the proximal promoter region of cd38 are underlined and in bold font.Respiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
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TNF-α-induced activation and specific binding of NF-κB to the consensus and cd38 putative binding sites in HASM cells Figure 1
TNF-α-induced activation and specific binding of NF-κB to the consensus and cd38 putative binding sites in 
HASM cells. Electrophoretic mobility gel shift demonstrating binding of nuclear proteins obtained from either control 
(untreated) or TNF-α-treated (50 ng/ml) HASM cells to labeled oligonucleotides corresponding the consensus (NF-κB-consen-
sus) or putative cd38 (NF-CD38) NF-κB binding sequences. Note NF-κB binding (indicated by horizontal arrow) in samples 
obtained from TNF-α-treated cells. Binding specificity was confirmed using a 100-fold excess of unlabeled oligonucleotide cor-
responding to either the consensus or putative sequences. Binding to the consensus and putative cd38 sequences is abolished 
by excess unlabeled putative sequence (shown by vertical arrows). SP1 oligonucleotides were used as a nonspecific competitor 
to confirm the specificity of the binding. FP: Free Probe in this and subsequent figures; T: TNF-α. Representative of 4 different 
assays.Respiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
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using specific antibodies. TNF-α increased the specific
binding of nuclear proteins to consensus (Figure 1) as
well as putative cd38 NF-κB sites (Figure 1), which was
effectively competed with excess unlabeled consensus or
putative sequences (Figure 1). EMSA also demonstrated
that TNF-α increased the specific binding of nuclear pro-
teins to the AP-1 consensus oligonucleotide sequence
(Figure 2) and the putative cd38 AP-1 sites 1, 4 and 6
(referred to as AP1–1, AP1–4 and AP1–6 respectively),
with the strongest binding to AP1–4 (Figure 2). Strong
competition for binding to the consensus AP-1 sequence
was observed with excess unlabeled AP1–4 sequence (Fig-
ure 3). AP-1 binding to the putative AP1–4 was confirmed
by a gel supershift assay with anti-c-fos antibodies (Figure
3).
Glucocorticoid receptor (GR) binding to consensus GRE
and putative GREs from cd38 sequences were performed
using nuclear extract obtained from dexamethasone-
treated HASM cells. Dexamethasone increased the bind-
ing of nuclear proteins to putative cd38 GRE sites 1, 3
(slight increase) and 4, but not to the GRE site 2 (Figure
4). This binding was inhibited with the respective excess
unlabeled oligonucleotide sequences. To examine the
direct binding of GR to putative GRE sites, we performed
EMSA with recombinant human GR protein. There was
binding of recombinant GR to labeled oligonucleotide
putative cd38 GRE sites 1, 3 and 4 (Figure 5) as well as
consensus GRE sequence (Figure 6). The binding of GR to
the putative cd38 GRE sites 1, 3 and 4 was inhibited by
excess unlabeled oligonucleotide sequences (Figure 5).
Furthermore, the GR binding to the labeled consensus
GRE sequence was inhibited by excess unlabeled cd38
putative GRE1, but not by the other putative GRE
sequences (Figure 6) as well as by GRE-TAT, a GRE site
from tyrosine aminotransferase gene (Figures 6). There
was no binding of GR to an irrelevant sequence, as shown
by a lack of binding to CREB binding sites (Figure 6). The
specificity of GR binding to the consensus GRE sequence
was further substantiated by gel supershift with an anti-
GR antibody. The EMSA with HASM nuclear extract and
putative GRE sites showed several binding complexes
(Figure 4), which is not unexpected since GR is known to
interact with many co-activators in the nucleus [15,16].
TNF-α-induced activation of AP-1 in HASM cells Figure 2
TNF-α-induced activation of AP-1 in HASM cells. Binding of nuclear proteins to labeled oligonucleotides corresponding 
to the AP-1 consensus (A) or putative cd38 (B) binding sequences. The specificity of binding was confirmed with excess unla-
beled consensus or putative AP-1 oligonucleotide sequences as a specific competitor, and SP1 as a nonspecific competitor. 
Anti-c-jun or -c-fos antibodies was used for the gel supershift assay. Panel A: TNF-α-induced increased binding to the consen-
sus AP-1 sequence (horizontal arrow) and gel supershift in the presence of an anti-c-Jun antibody (c-Jun). Note decreased bind-
ing in the presence of unlabeled consensus AP-1 (AP1) or with mutated AP-1 (AP-1 mut). Panel B: TNF-α-induced increased 
binding to labeled putative cd38 AP-1 sites 1, 4 and 6 (indicated by arrows and labeled AP1–1, AP1–4 and AP1–6 respectively), 
with the strongest binding to AP1–4.
A BRespiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
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Activation of the cd38 promoter requires NF-κB and AP-1, 
and is inhibited by dexamethasone
The EMSA studies revealed that TNF-α increased the bind-
ing of nuclear proteins to the putative NF-κB site, and to
some of the putative AP-1 sites in the cd38 promoter. Like-
wise, dexamethasone increased the binding of nuclear
proteins selectively to some of the putative cd38 GREs. To
investigate whether TNF-α modulates cd38  promoter
activity directly, HASM cells were transiently transfected
with a cd38 promoter-driven luciferase reporter construct.
In the initial studies, we used the 3 kb promoter (Figure 7)
and a truncated 1.8 kb promoter that lacks the NF-κB site
and the AP1–4 site that exhibited very strong binding fol-
lowing TNF-α treatment. HASM cells were transiently
transfected with the promoter constructs and luciferase
activity was determined following exposure to TNF-α.
TNF-α caused an increase in luciferase activity of the 3 kb
promoter, but not the truncated 1.8 kb promoter, and
dexamethasone decreased the TNF-α-induced activation
of the 3 kb promoter (Figure 8)). To determine the tran-
scription factor binding sites within the 3 kb promoter
that are involved in the regulation of CD38 expression,
HASM cells were transfected with site directed mutated
constructs. For these studies, cd38  promoter luciferase
constructs mutated at the NF-κB site or the AP1–4 site, or
at both of these sites were used. Following exposure to
TNF-α, luciferase activity was abolished in the promoter
constructs with mutations of either the NF-κB or the AP1–
4 sites, or mutation in both the sites (Figure 8). The EMSA
results and the decreased activation of the promoter with
mutations (that lack the NF-κB and the dominant AP1–4
binding sites) confirm a functional role for NF-κB and
AP1–4 in the transcriptional regulation of CD38. Gluco-
corticoid regulation also involves binding to cd38 GREs
and inhibition of NF-κB- and AP-1-dependent transcrip-
tion.
Discussion
Airway hyperresponsiveness to non-specific stimuli is a
hallmark of asthma. In this regard, airway smooth muscle
has a role in the regulation of airflow and in maintaining
airway caliber. Airway smooth muscle contractility
TNF-α-induced activation and specific binding of AP-1 to the consensus and cd38 putative binding sites in HASM cells Figure 3
TNF-α-induced activation and specific binding of AP-1 to the consensus and cd38 putative binding sites in 
HASM cells. Left Panel: Nuclear protein binding to AP-1 consensus sequence and competition for AP-1 binding with unla-
beled oligonucleotide consensus (AP-1 con) and putative AP-1 sequences (labeled AP1–1 to AP1–6). Note decreased binding 
with AP-1 con, and AP1–4 and AP1–6 unlabeled sequences. Right Panel: Nuclear protein binding to labeled oligonucleotide 
AP1–4 sequence (arrow on left), which is abolished in the presence of excess unlabeled oligonucleotide AP1–4 sequence 
(labeled AP1–4), but not by a non-specific competitor (SP1). Gel supershift with anti-c-fos antibodies (arrow and labeled Fos). 
Representative of 4 different assays.Respiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
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requires the elevation of intracellular calcium and the
CD38/cADPR signaling pathway has a central role in cal-
cium homeostasis [7]. A previous study from our labora-
tory demonstrated that CD38 expression is up-regulated
by the proinflammatory cytokine TNF-α resulting in an
increased intracellular calcium response to multiple ago-
nists [5]. The increased CD38 expression is down-regu-
lated by the anti-inflammatory glucocorticoid
dexamethasone through inhibition of NF-κB [9]. In this
study, we characterized a 3 kb fragment that functions as
a promoter of the cd38 gene. We also show that the cd38
promoter contains one NF-κB, six AP-1, and four GRE
putative binding sites. TNF-α caused activation of the 3 kb
promoter fragment, which is decreased when the NF-κB
and/or the AP1–4 sites were mutated. The EMSA studies
confirmed direct binding of NF-κB and AP-1 to putative
cd38 binding sites. Dexamethasone reversed the TNF-α-
induced activation of the 3 kb promoter and increased the
binding of GR to consensus and putative cd38  GREs.
These studies demonstrate an important role of NF-κB
and AP-1 in the regulation of CD38 expression in HASM
cells. Furthermore, glucocorticoids decrease CD38 expres-
sion transcriptionally by directly binding to the putative
cis-acting binding sites and also by interfering with the
transcription factors.
The cd38 gene has been localized on chromosome 4 in
human and chromosome 5 in the mouse [17]. The CD38
protein is encoded by a >80 kb length gene comprising of
8 exons. Studies from other laboratories have revealed
binding sites for several transcription activating factors in
the cd38 gene [17,18]. Previous studies have shown the
Specific binding of GR to cd38 putative GRE binding sites Figure 4
Specific binding of GR to cd38 putative GRE binding sites. Electrophoretic mobility gel shift assays demonstrating bind-
ing of nuclear proteins obtained from control or dexamethasone-treated HASM cells to labeled oligonucleotide putative cd38 
GRE sites. To confirm specificity of binding, unlabeled oligonucleotide putative cd38 GRE sequences were used as a specific 
competitor. Dexamethasone induced binding of nuclear proteins to oligonucleotides corresponding to the cd38 putative GRE 
binding sequences 1, 3 and 4 (labeled GRE1 to GRE4), and decreased binding in the presence of the respective unlabeled oligo-
nucleotide sequences. The binding to GRE3 is weaker compared to the other putative GRE motifs. Note that there is no 
increase in nuclear protein binding to GRE2 by dexamethasone compared to untreated control.Respiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
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absence of a canonical TATA or CAAT box sequences in
the cd38 promoter region, suggesting that transcription
can be initiated at multiple sites [19]. However, TATA-less
promoters with transcription start sites such as an initiator
(Inr) sequence or binding sites for the PU.1 transcription
factor have been described in myeloid and B cells [20].
The G/C rich region upstream of ATG may also support
the initiation of transcription. In addition, consensus
binding sites for T cell transcription factor (TCF-1α), Ig
gene box enhancer motifs (µE1, µE5 and κE2), nuclear
factor-IL-6 and IFN-responsive factor-1 have been
described [21]. Kishimoto et al [13] have reported the
DR5 repeat (TGACCCgaaagTGCCCC) within intron 1,
which has a role in retinoic acid induction of CD38
expression in HL-60 cells. Studies from other laboratories
have revealed a ~900 bp CpG island spanning exon 1 and
the 5' end of intron 1 with a binding sequence for Sp1, a
transcription factor that regulates the constitutive expres-
sion of CD38 [22]. Furthermore, a glucocorticoid
response element and an estrogen binding motif have also
been described in the promoter region of cd38 [22]. In
support of a functional role of the estrogen binding motif
within the promoter, our previous studies demonstrate
the up-regulation of CD38 expression by estrogen in uter-
ine smooth muscle [23-25]. Taken together, it is likely the
transcriptional regulation of CD38 expression by these
hormones may have a physiological role in uterine motil-
ity.
Inflammatory cytokines such as TNF-α, IL-1β and IFN-γ
play an important role in diseases such as asthma [26,27].
Previous investigations have demonstrated that the levels
of inflammatory cytokines are elevated in the bronchoal-
veolar lavage fluid obtained from asthmatic subjects
[26,27]. TNF-α has been shown to increase the expression
of a variety of genes resulting in functional changes in air-
way smooth muscle cells [28,29]. Recent investigations
from our laboratory have shown that the inflammatory
cytokines increase the expression of CD38 in human air-
way smooth muscle cells [5,7,8]. The regulation of CD38
expression by TNF-α in HASM cells involves NF-κB and
AP-1 activation and signaling through the p38 and JNK
Binding of recombinant glucocorticoid receptor (GR) to cd38 putative GRE sequences Figure 5
Binding of recombinant glucocorticoid receptor (GR) to cd38 putative GRE sequences. Binding of recombinant 
glucocorticoid receptor (GR) to cd38 putative GRE sequences showing increased binding to GRE sequences 1, 3 and 4, and 
competition for binding with the respective unlabeled oligonucleotide sequences (indicated by arrows).Respiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
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Binding of recombinant glucocorticoid receptor (GR) to consensus GRE sequences Figure 6
Binding of recombinant glucocorticoid receptor (GR) to consensus GRE sequences. Binding of recombinant GR to 
labeled consensus GRE sequence (lane 2 and indicated by horizontal arrow), competition for binding with cd38 putative GRE 
sequences (labeled GRE1 to GRE4, lanes 7–10), and gel supershift with anti-GR antibodies (Anti-GR, lane 5). Note decreased 
binding in the presence of either 100- (100 × GRE-con, lane 3) or 200- (200 × GRE-con, lane 4) fold excess unlabeled consen-
sus sequence or 100-fold GRE-TAT (lane 11, vertical arrow), a known GRE binding sequence. Competition assays with excess 
unlabeled cd38 putative GRE sequences reveal decreased binding only in the presence of the GRE1 (lane 7, vertical arrow). 
Note gel supershift in the presence of an anti-GR antibody (shown as anti-GR). Lanes on extreme right show no specific bind-
ing of GR to an irrelevant binding site (shown here for CREB, lanes 12 and 13). Representative of 4 assays.Respiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
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MAP kinases [9,10]. TNF-α-induced CD38 expression in
airway smooth muscle cells involves signaling via the
TNFR1 receptor and IFNβ that is generated in response to
TNF-α [30]. Thus, the induction of CD38 expression by
TNF-α may involve regulation by multiple transcription
factors such as interferon regulatory factor-1, NF-κB, AP-1
and possibly others. In this context, sequence analysis of
the cloned human cd38 promoter also reveals 4 putative
binding sites for the transcription factor c/EBPβ, three of
which are within a region upstream of the NF-κB site. The
1.8 kb truncated promoter construct that was not acti-
vated by TNF-α also contains these c/EBPβ sites. The role,
if any, of this transcription factor in the regulation of
CD38 expression in HASM cells remains to be deter-
mined.
Glucocorticoids are used extensively as anti-inflammatory
therapy in asthma [11] and their mechanism(s) of action
are complex [31]. The nuclear translocation of the GR
complex and its binding to specific DNA motifs results in
both transactivation and repression of a variety of genes
[12,32-34]. The presence of GREs provides a basis for tran-
scriptional regulation of CD38 expression. The GR com-
plex also interferes with NF-κB binding to DNA [35,36].,
thereby decreasing the expression of genes that are regu-
lated by this transcription factor. We have previously dem-
onstrated inhibition of NF-κB activation by
dexamethasone in HASM cells exposed to TNF-α [9]. This
inhibition results from decreased NF-κB expression and
increased IκB expression following exposure to dexameth-
asone. This mechanism of regulation of NF-κB activation
has been described in other cell systems [33,37]. In pre-
liminary studies, we have also noticed decreased AP-1
activation in TNF-α-stimulated cells by dexamethasone.
The mechanism of glucocorticoid-mediated reduction of
CD38 expression may involve steric hindrance for the
binding of NF-κB and AP-1 to their binding sites and/or
interference with transactivation. The actions of glucocor-
The cloned 3 kb cd38 promoter showing the location of the putative binding sites for NF-κB, AP-1 and GR (labeled NF-κB, AP- 1 and GRE) Figure 7
The cloned 3 kb cd38 promoter showing the location of the putative binding sites for NF-κB, AP-1 and GR 
(labeled NF-κB, AP-1 and GRE). Location of the putative binding sites for NF-κB, AP-1, and GRE on the cd38 promoter, 
the 3 kb (Full) promoter, the truncated 1.8 kb promoter (Truncated), and promoter constructs with mutations in the binding 
sites for NF-κB or AP1–4 or both binding sites (NF-AP-mut, NF-mut and AP-mut). The promoter was cloned in front of a luci-
ferase reporter gene in the pGL3 plasmid and was used to transfect HASM cells.Respiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
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ticoids have been demonstrated for the NF-κB- and AP-1-
mediated regulation of other genes [34,38-43].
In this study, we have identified 4 glucocorticoid response
elements in the putative promoter region of the cd38 gene
as well as response elements for AP-1 and NF-κB (Table
1). Inhibition of NF-κB or AP-1 activation, or MAPK sign-
aling using pharmacological and molecular tools has con-
firmed their role in the regulation of CD38 expression
[9,10]. The identified putative sites for AP-1 and GRE also
exhibit strong binding in EMSA upon exposure to TNF-α
and dexamethasone respectively. The AP1–4 site (residing
between -2798 to -2789 bp) that shows very strong bind-
ing also appears to be functionally important in the acti-
vation of the promoter, since mutation of this site
profoundly affected TNF-α-induced activation of CD38
expression. With respect to NF-κB, mutation of the only
identifiable binding site also resulted in abolition of
CD38 transcription. It is worth noting that binding to this
site was weak compared to the consensus NF-κB sequence
binding, although competition with the unlabelled puta-
tive sequence effectively abolished the strong binding to
the consensus sequence. In the presence of dexametha-
sone, there was complete reversal of TNF-α-induced acti-
vation of the promoter, indicating direct transcriptional
regulation of CD38 expression by glucocorticoids in
HASM cells. These findings implicate the importance of
NF-κB and AP-1, and the GRE within the proximal pro-
moter region in the regulation of CD38 gene expression.
The results of promoter transfections and EMSAs with
cd38  putative GREs demonstrate transcriptional repres-
sion of CD38 expression by glucocorticoids. However,
glucocorticoids are also known to repress gene expression
in HASM cells through inhibition of histone acetylation
[44]. Evidence for glucocorticoid resistance of CD38
expression in HASM cells has also been reported when a
combination of cytokines is used as the stimulus as
opposed to the single stimulus used in the present study.
In this context, a recent study showed that in the com-
bined presence of TNF-α and IFN-γ or IFN-β, CD38
expression in HASM cells becomes refractory to glucocor-
ticoids [45]. The mechanism appears to involve induction
of the dominant negative GR-β. Thus, the glucocorticoid
regulation of CD38 expression in airway smooth muscle
cells is very complex and appears to depend on the stimu-
lus or combination of stimuli used.
In a recent study, Sun et al described the structure of the
promoter region of rabbit cd38 and provided evidence for
the functional regulation of CD38 expression in osteob-
Activation of the cd38 promoter in the HASM cells Figure 8
Activation of the cd38 promoter in the HASM cells. Luciferase activity was measured as an index of promoter activation 
with the Renilla luciferase activity (pRL-TK) to normalize for transfection efficiency. The normalized luciferase activity is 
expressed as the fold change compared to the control. Left Panel: Activation of the full length promoter and the truncated 
promoter. TNF-α (T) causes activation of the 3 kb promoter as compared to control (C), which is inhibited in the presence of 
dexamethasone (D+T). Truncated promoter: There is no activation of the truncated promoter by TNF-α. Right Panel: TNF-
α causes activation of the 3 kb promoter (3 kb), but not the constructs with mutations in NF-κB or/and AP-1 site 4 (labelled 
NF-AP mut, NF mut and AP mut). Representative of 3 different assays.Respiratory Research 2008, 9:26 http://respiratory-research.com/content/9/1/26
Page 13 of 14
(page number not for citation purposes)
last and osteoclast cell lines [14]. In a region encompass-
ing 1.5 kb of the promoter obtained from a rabbit
genomic DNA library, the authors identified potential
binding sites for SP-1, AP-1, and AP-4. Using promoter-
reporter assays similar to those described in the present
studies, with a 1.5 kb promoter and several deletion
mutants, they were able to demonstrate a functional AP-1
site in the 1.0 kb promoter fragment. There also appears
to be cell-type specific activation of the promoter as
shown by studies with deletion mutagenesis.
Conclusion
In the present study, we describe NF-κB and AP-1 binding
motifs within the cd38 promoter that exhibit very strong
binding of nuclear proteins, mutations of which decrease
promoter activation and hence may be functionally rele-
vant. Our results also support the role of multiple tran-
scription factors in the regulation of CD38 expression in
HASM cells. Furthermore, we demonstrate a direct tran-
scriptional control of CD38 expression by glucocorti-
coids, although we have not identified specific GREs
within the proximal promoter region involved in this reg-
ulation. The fact that CD38 expression is regulated by
cytokines and transcription factors that are implicated in
asthma, and inhibited by glucocorticoids which are a
mainstay of asthma therapy makes this an attractive ther-
apeutic target.
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